TY - JOUR
T1 - Cerebral blood flow and cognitive functioning in patients with disorders along the heart–brain axis
T2 - Cerebral blood flow and the heart–brain axis
AU - Heart–Brain Connection consortium
AU - Leeuwis, Anna E.
AU - Hooghiemstra, Astrid M.
AU - Bron, Esther E.
AU - Kuipers, Sanne
AU - Oudeman, Eline A.
AU - Kalay, Tugba
AU - Brunner-La Rocca, Hans Peter
AU - Kappelle, L. Jaap
AU - van Oostenbrugge, Robert J.
AU - Greving, Jacoba P.
AU - Niessen, Wiro J.
AU - van Buchem, Mark A.
AU - van Osch, Matthias J.P.
AU - van Rossum, Albert C.
AU - Prins, Niels D.
AU - Biessels, Geert Jan
AU - Barkhof, Frederik
AU - van der Flier, Wiesje M.
N1 - Funding Information:
G.J. Biessels has been funded by the Dutch Heart Foundation (grant 2010T073), ZonMW (Vici grant 918.16.616), The Netherlands Organisation for Health Research and Development and European Union Horizon 2020 (grant agreement no. 666881, SVDs@target).
Funding Information:
This work was supported by the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation (CVON 2018‐28 & 2012‐06 Heart Brain Connection), Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences.
Funding Information:
Research programs of W.M. van der Flier have been funded by ZonMW, NWO, EU‐FP7, Alzheimer Nederland, Cardiovasculair Onderzoek Nederland, stichting Dioraphte, Gieskes‐Strijbis fonds, Pasman Stichting, Boehringer Ingelheim, Piramal Imaging, Roche BV, Janssen Stellar, Biogen, and Combinostics. All funding is paid to her institution.
Funding Information:
F. Barkhof is supported by the NIHR biomedical research centre at UCLHF. Barkhof serves as a consultant for Biogen‐Idec, Janssen Alzheimer Immunotherapy, Bayer‐Schering, Merck‐Serono, Roche, Novartis, Genzyme, and Sanofi‐aventis.F. Barkhof has received sponsoring from EU‐H2020, NWO, SMSR, TEVA, Novartis, Toshiba, and Imi and serves on the editorial boards of , and . Radiology, Brain, Neuroradiology, MSJ Neurology
Funding Information:
M.J.P. van Osch has received research funding from Philips, the Netherlands Organisation for Scientific Research (NWO), and European Union Horizon 2020 and serves on the editorial boards of and in Biomedicine. JCBFM NMR
Funding Information:
E.E. Bron and J.P. Greving have been funded by the Dutch Heart Foundation.
Publisher Copyright:
© 2020 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.
PY - 2020
Y1 - 2020
N2 - Introduction: We examined the role of hemodynamic dysfunction in cognition by relating cerebral blood flow (CBF), measured with arterial spin labeling (ASL), to cognitive functioning, in patients with heart failure (HF), carotid occlusive disease (COD), and patients with cognitive complaints and vascular brain injury on magnetic resonance imaging (MRI; ie, possible vascular cognitive impairment [VCI]). Methods: We included 439 participants (124 HF; 75 COD; 127 possible VCI; 113 reference participants) from the Dutch multi-center Heart–Brain Study. We used pseudo-continuous ASL to estimate whole-brain and regional partial volume-corrected CBF. Neuropsychological tests covered global cognition and four cognitive domains. Results: CBF values were lowest in COD, followed by VCI and HF, compared to reference participants. This did not explain cognitive impairment, as we did not find an association between CBF and cognitive functioning. Discussion: We found that reduced CBF is not the major explanatory factor underlying cognitive impairment in patients with hemodynamic dysfunction along the heart–brain axis.
AB - Introduction: We examined the role of hemodynamic dysfunction in cognition by relating cerebral blood flow (CBF), measured with arterial spin labeling (ASL), to cognitive functioning, in patients with heart failure (HF), carotid occlusive disease (COD), and patients with cognitive complaints and vascular brain injury on magnetic resonance imaging (MRI; ie, possible vascular cognitive impairment [VCI]). Methods: We included 439 participants (124 HF; 75 COD; 127 possible VCI; 113 reference participants) from the Dutch multi-center Heart–Brain Study. We used pseudo-continuous ASL to estimate whole-brain and regional partial volume-corrected CBF. Neuropsychological tests covered global cognition and four cognitive domains. Results: CBF values were lowest in COD, followed by VCI and HF, compared to reference participants. This did not explain cognitive impairment, as we did not find an association between CBF and cognitive functioning. Discussion: We found that reduced CBF is not the major explanatory factor underlying cognitive impairment in patients with hemodynamic dysfunction along the heart–brain axis.
UR - http://www.scopus.com/inward/record.url?scp=85084475927&partnerID=8YFLogxK
U2 - 10.1002/trc2.12034
DO - 10.1002/trc2.12034
M3 - Article
AN - SCOPUS:85084475927
VL - 6
JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions
JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions
SN - 2352-8737
IS - 1
M1 - e12034
ER -
